US 12,338,282 B2
Anti-Notch3 antibody
Heidi Okamura, Brookline, MA (US); William M. Winston, Jr., Marlborough, MA (US); Laura Poling, Boston, MA (US); and Alisa C. Bell, Bedford, MA (US)
Assigned to AVEO Pharmaceuticals, Inc., Boston, MA (US)
Filed by AVEO Pharmaceuticals, Inc., Boston, MA (US)
Filed on Oct. 7, 2021, as Appl. No. 17/450,282.
Application 17/450,282 is a continuation of application No. 16/097,489, granted, now 11,142,573, issued on Oct. 12, 2021, previously published as PCT/US2017/030156, filed on Apr. 28, 2017.
Claims priority of provisional application 62/460,371, filed on Feb. 17, 2017.
Claims priority of provisional application 62/329,729, filed on Apr. 29, 2016.
Prior Publication US 2022/0235127 A1, Jul. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/10 (2006.01); C12N 5/12 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01); C07K 14/71 (2006.01)
CPC C07K 16/28 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C12N 5/10 (2013.01); C12N 5/12 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 14/71 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. A method of inhibiting or reducing ligand-induced Notch3 activity in a mammal, the method comprising exposing the mammal to an effective amount of an antibody that binds human Notch3, wherein the antibody comprises:
(a) an immunoglobulin heavy chain variable region (VH) comprising a CDRH1, CDRH2, and CDRH3, wherein the CDRH1, CDRH2, and CDRH3 comprise the CDRH1, CDRH2, and CDRH3 of a VH amino acid sequence set forth in SEQ ID NO: 6; and
(b) an immunoglobulin light chain variable region (VL) comprising a CDRL1, CDRL2, and CDRL3, wherein the CDRL1, CDRL2, and CDRL3 comprise the CDRL1, CDRL2, and CDRL3 of a VL amino acid sequence set forth in any one of SEQ ID NO: 10, 23, 24, 25, 26, 27, 28, 29, 37, 38, or 39.